

^1H and ^{13}C NMR Assignment of Sunitinib Malate in Aqueous Media

Myungjo J. Kim, Jong Hoa Ok, Chul Hwan Kim, and Joo Young Oh

R&D Center, SCAI Therapeutics, Inc., Daejeon 34013, Republic of Korea

mjk@scaitrx.com

[Abstract]

Despite expanding therapeutic application of sunitinib and advances in its formulation, pharmacochemical and spectroscopical study on its aqueous solution is rather insufficient due to poor solubility of its base or salt form. In this report, ^1H (900 MHz) and ^{13}C (225 MHz) NMR spectra of sunitinib malate in $\text{H}_2\text{O}/\text{D}_2\text{O}=9/1$ have been analyzed, whose spectral peaks have been assigned to each hydrogen and carbon atom, assisted by a combination of two-dimensional homo- and heteronuclear NMR: COSY, HSQC-DEPT, and HMBC. The assignment of labile H-N hydrogens in ^1H NMR spectrum is of particular interest in aqueous media, where such labile hydrogens could be potentially affected by intermolecular interactions (*e.g.*, hydrogen bonding) with co-solvated constituents. Peak splitting patterns and corresponding $^nJ_{\text{H-H}}$, $^nJ_{\text{H-F}}$, and $^nJ_{\text{C-F}}$ coupling constants observed in each assigned spectrum have been jointly discussed, and $^nJ_{\text{C-F}}$ coupling constants were compared to those taken in DMSO- d_6 .

Sunitinib is a versatile tyrosine kinase inhibitor, sold under the brand name Sutent® by Pfizer as its malate salt form.¹ It is currently used to treat renal cell carcinoma and gastrointestinal stromal tumors through its antitumor and antiangiogenic activities, while more of its activities and applications are being explored. Further research endeavors regarding its broader range of application against leukemia and solid tumors (*e.g.*, non-small-cell lung cancer, pancreatic neuroendocrine tumors, and metastatic breast cancer) are currently ongoing.² Besides oncological utilization, treatment of age-related macular degeneration is one of its other notable applications which led us to constitute aqueously dispersed sunitinib malate in an eyedrop formulation recently.³ As of January 2022, 27 clinical trials in 40 countries for sunitinib alone or in combination with other drug(s), are under way for novel applications towards paraganglioma, thymoma, prostate cancer, stomach neoplasm, and more;⁴ allowing the medicinal research community to expect greater therapeutic potential.

Given the expanding application of sunitinib base or its malate salt form, adequate pharmaceutical formulation research as well as pharmacochemical study should follow accordingly. For instance, though there have been various attempts to constitute sunitinib malate into novel pharmaceutical formulations, solubility issue that the ionic compound being poorly soluble in water⁵ has been a major bottleneck. Recent reports describe different types of nanoparticle,⁶ suspension,⁷ and micelle⁸ formulations, where spectroscopical method such as NMR is particularly important to determine intermolecular interaction between pharmaceutical ingredients. However, on its ¹H and ¹³C NMR spectra, each spectral peak signal has not been clearly assigned to each hydrogen and carbon atom in its chemical structure. There have only been a few reports of incomplete assignments in CDCl₃ and DMSO-d₆ to date.^{9,10} The assignment of labile H–N hydrogens is of particular interest in aqueous formulations, in order to identify which H–N bond is responsible for intermolecular interaction (*e.g.*, hydrogen bonding) with solvated salt, additive, and solvent. Herein, we report the ¹H and ¹³C NMR assignment of sunitinib malate in aqueous media, including the assignment of major labile H–N hydrogens.




Figure 1. Labelling of nitrogen and oxygen atoms with labile hydrogens, and skeletal carbon atoms of sunitinib malate.

As shown in **Figure 1**, nitrogen and oxygen atoms attached to labile hydrogens — H–N₁, H–N₁₂, H–N₁₉, H–N₂₂, H–O₂₉, and H–O₃₀ — as well as skeletal carbon atoms were labelled. In order to acquire ¹H spectrum in aqueous media with no loss of labile hydrogen peaks, H₂O solvent with additional D₂O (10%, v/v) was used instead of pure D₂O, where water-suppression method was used. As a result, spectral peaks of labile H–N hydrogens H–N₁, H–N₁₂, and H–N₁₉ were well observed with the peak integration of 0.43H, 0.85H, and 0.88H, respectively (**Figure S1**). On the other hand, H–O₂₉, H–O₃₀, and H–N₂₂ were not observed where the first two underwent rapid deuterium-hydrogen

exchange.

It is notable that none of the aromatic peaks were overlapped by each other in contrast to the previously reported spectrum acquired in DMSO-d₆.⁹ Chemical shift of the C₁₆ and C₁₇ methyl groups on the pyrrole ring (at around 1.88 ppm and 1.86 ppm) were much lower than those from the spectrum acquired in DMSO-d₆ so that they did not overlap with two H-C₂₇ doublets of malate at around 2.72 and 2.54 ppm as well. Due to the baseline affected by the water-suppression near 4.80 ppm, peak integration for H-C₂₆ was rather inaccurate (0.73H). H-C₂₃ quartet at 3.22 ppm and H-C₂₁ triplet at 3.21 ppm with similar intensities, were found to partially overlap each other to appear as a quintet-like structure as shown in **Figure 2(a)**. Aromatic hydrogen peaks of the indolinone ring, H-C₄, H-C₆, and H-C₇, as well as *exo*-cyclic vinyl H-C₁₀, are shown in **Figure 2(b)**, where the first three were split into doublet-of-doublets and a triplet-of-doublet, due to a combination of hydrogen-fluorine and hydrogen-hydrogen couplings across the ring. The J-coupling constants were estimated to be ³J_{H-F} = 8.92 Hz (*ortho*, H-C₄), ⁴J_{H-H} = 2.43 Hz (*meta*, H-C₄), ³J_{H-F} = 8.67 Hz (*ortho*, H-C₆), ⁴J_{H-H} = 2.17 Hz (*meta*, H-C₆), ³J_{H-H} = 8.23 Hz (*ortho*, H-C₆), ⁴J_{H-F} = 4.24 Hz (*meta*, H-C₇), and ³J_{H-H} = 7.90 Hz (*ortho*, H-C₇).




Figure 2. (a) J-coupling tree diagrams of partially overlapped H-C₂₃ (quartet) and H-C₂₁ (triplet) peaks (left). (b) J-coupling tree diagrams of H-C₄ (doublet-of-doublet), H-C₆ (triplet-of-doublet), and H-C₇ (doublet-of-doublet) peaks in that order from the downfield (right). (Chemical shift: ppm)

¹³C carbon NMR was acquired in the same environment which gave good signal-to-noise ratios with respect to peaks for carbonyl carbons and aromatic carbons that do not possess any hydrogen

atom (**Figure S2**). Carbon-fluorine coupling constants from the aromatic hydrogen peaks of the indolinone ring, were estimated to be $^1J_{C-F} = 235.62$ Hz (*ipso*, C₅), $^2J_{C-F} = 24.78$ Hz (*ortho*, C₄), $^2J_{C-F} = 24.19$ Hz (*ortho*, C₆), $^3J_{C-F} = 8.57$ Hz (*meta*, C₇), and $^3J_{C-F} = 9.01$ Hz (*meta*, C₉), where no *para* coupling was observed (**Figure 3**). It is uncertain that singlets of *ipso* carbon doublet have particularly asymmetric peak intensities throughout repeated experiments, where that of ^{13}C spectrum acquired in DMSO-d₆ showed similar singlet peak intensities within the corresponding doublet. In-house measurement of the coupling constants in DMSO-d₆ at 100 MHz resulted in $^1J_{C-F} = 234.33$ Hz (*ipso*, C₅), $^2J_{C-F} = 25.52$ Hz (*ortho*, C₄), $^2J_{C-F} = 24.21$ Hz (*ortho*, C₆), $^3J_{C-F} = 8.52$ Hz (*meta*, C₇), $^3J_{C-F} = 9.53$ Hz (*meta*, C₉), and $^4J_{C-F} = 3.09$ Hz (*para*, C₈) (**Figure S6**).




Figure 3. Split ^{13}C peaks of aromatic carbons *ipso*, *ortho*, and *meta* to the fluorine atom: C₅ (*ipso*), C₉ (*meta*), C₆ (*ortho*), C₇ (*meta*), and C₄ (*ortho*) in that order from the downfield. (Chemical shift: ppm)

Throughout a HSQC-DEPT experiment, we could easily differentiate methylene carbons (anti-phase signals) between 3.60 and 2.40 ppm from the rest of the spectrum: CH₂ moieties on the ammonium tether (H-C₂₀, H-C₂₁, and H-C₂₃) and the malate backbone (H-C₂₇) (**Figure S3**). Methyl groups at the end of the tether and on the pyrrole ring, showed the in-phase signals in the upfield region (2.00 – 1.10 ppm). Each aromatic hydrogen peak was assigned to the adjacent carbon within the indolinone moiety (H-C₄, H-C₆, and H-C₇) as well as *exo*-cyclic vinyl hydrogen to its skeletal carbon (H-C₁₀), where they exhibited in-phase signals on the two-dimensional spectrum as well. COSY spectrum (**Figure S4**) showed clear off-diagonal signals to confirm the *ortho* relationship between

H-C₆ and H-C₇, and to confirm the connectivity through the ammonium tether.




Figure 4. Summary of HMBC correlations within sunitinib malate in aqueous media.




Figure 5. Key HMBC correlations from aromatic hydrogen peaks and *exo*-cyclic vinyl hydrogen peak.
(Chemical shift: ppm)

113 **Table 1.** Summarized NMR peak assignment table of sunitinib malate in H₂O/D₂O=9/1 (v/v).

¹ H/ ¹³ C Assignment	Chemical Shift ^a (δ _H) (ppm)	Chemical Shift ^a (δ _C) (ppm)	J-Coupling Constants ^b (Hz)	HSQC-DEPT Correlations ^c	HMBC Correlations	COSY Correlations
1	9.582				C ₂ , C ₃ , C ₈ , C ₉	
2		169.097				
3		114.645				
4	6.550(dd)	104.281(d)	2.43, 8.92, (24.78)	C ₄ (+)	C ₃ , C ₅ , C ₆ , C ₈	
5		158.392(d)	(235.62)			
6	6.414(td)	112.042(d)	2.17, 8.23, 8.67, (24.19)	C ₆ (+)	C ₄ , C ₅ , C ₈	H-C ₇
7	6.308(dd)	109.718(d)	4.24, 7.90, (8.57)	C ₇ (+)	C ₅ , C ₈ , C ₉	H-C ₆
8		133.221				
9		126.484(d)	(9.01)			
10	6.444	123.016		C ₁₀ (+)	C ₂ , C ₃ , C ₉ , C ₁₅	
11		125.866				
12	12.293				C ₁₁ , C ₁₃ , C ₁₄ , C ₁₅ , C ₁₇ , C ₁₈	
13		138.641				
14		115.996				
15		130.169				
16	1.875	10.053		C ₁₆ (+)	C ₁₁ , C ₁₄ , C ₁₅	
17	1.860	13.093		C ₁₇ (+)	C ₁₃	
18		168.029				
19	7.042				C ₁₈	H-C ₂₀
20	3.522(q)	34.782	6.42, 6.50, 6.50	C ₂₀ (−)	C ₁₈ , C ₂₁	H-C ₁₉ , H-C ₂₁
21	3.205(t)	51.180	6.41, 6.63	C ₂₁ (−)	C ₂₀	H-C ₂₀
22						
23	3.216(q)	48.251	6.69, 6.95, 6.95	C ₂₃ (−)	C ₂₁ , C ₂₄	H-C ₂₄
24	1.261(t)	8.454	7.19	C ₂₄ (+)	C ₂₃	H-C ₂₃
25 ^d		179.153				
26	4.296(dd)	68.676	4.32, 8.10	C ₂₆ (+)	C ₂₅ , C ₂₇ , C ₂₈	H-C ₂₇
27	2.724(dd); 2.535(dd)	40.248	4.31, 15.97; 8.11, 15.97	C ₂₇ (−)	C ₂₅ , C ₂₆ , C ₂₈	H-C ₂₆
28 ^d		176.502				

114 ^aSinglet unless otherwise stated; d: doublet; t: triplet; q: quartet; dd: doublet-of-doublet; td: triplet-of-doublet.115 ^bJ-coupling constant in ¹³C NMR is described in parenthesis. ^cIn-phase and anti-phase signals are denoted by
116 (+) and (−) signs, respectively. ^dDifferentiation between two carbonyl carbons of malate (C₂₅ and C₂₈) was not
117 viable due to the presence of both three-bond correlations (³J_{C-H}) from H₂₆ and H₂₇.118
119 HMBC spectrum (**Figure S5**) confirmed the connectivity throughout the structure via crucial long-
120 range correlations as summarized by arrows in **Figure 4**. HMBC correlations from the aromatic
121 hydrogen peaks of the indolinone ring and *exo*-cyclic vinyl hydrogen peak are shown in **Figure 5**
122 where key multi-bond couplings across the indolinone ring are exhibited. However, ¹³C peak

assignment of pyrrole ring carbons C₁₁, C₁₄, and C₁₅, is not fully settled unfortunately, due to (1) a missing long-range coupling from H-C₁₇ and/or H-N₁₉ for the absolute determination of the C₁₄ peak, and (2) a challenging differentiation of ²J_{C-H} from long-range couplings as HMBC-RELAY, H2BC, and ²J,³J-HMBC could not be utilized for non-hydrogenated carbons.¹¹ Since optimization of pulse sequence length was not viable, the HMBC correlation from H₁₀ into the pyrrole ring was assumed to be a ³J_{C-H} coupling, as ²J_{C-H} couplings often tend to be weak or missing in conventional HMBC. Summarized peak table for each hydrogen and carbon atom assigned, including peak multiplicity, J-coupling constant, and HSQC-DEPT/HMBC/COSY correlations, is provided in **Table 1**.

In conclusion, we report the first complete ¹H and ¹³C NMR assignment of sunitinib malate in aqueous media, assisted by a combination of two-dimensional homo- and hetero-nuclear NMR, COSY, HSQC-DEPT, and HMBC. H₂O/D₂O co-solvent system was used in order to identify major labile H-N hydrogens which could potentially play crucial roles in aqueous intermolecular interactions. Peak splitting patterns in each assigned spectrum are also discussed as well as the corresponding ⁿJ_{H-H}, ⁿJ_{C-H}, and ⁿJ_{C-F} coupling constants measured. Each assigned spectrum showed substantial difference from those acquired in aprotic solvents in respect of chemical shift and peak splitting. We believe that the assignment would be useful for further formulation research of sunitinib malate and relevant pharmaceutical moieties.

[Acknowledgement]

This work is supported by SCAI Therapeutics, Inc. We are grateful to Eun-Hee Kim and Hae-Kap Cheong (Korea Basic Science Institute) for the acquisition of the NMR spectra. We thank Kyoung-Hee Kim and Geewoo Nam (SCAI Therapeutics Inc.) for fruitful discussions.

[Associated Content]

Experimental procedure and NMR spectra with detailed acquisition parameters are available in Supporting Information via ChemRxiv website (<https://chemrxiv.org>).

[References]

¹Faivre *et al.*, *Nature Reviews Drug Discovery* **2007**, *6*, 734.

²(a) Fiedler *et al.*, *British Journal of Haematology* **2015**, *169*, 694. (b) Novello *et. al.*, *Journal of Thoracic Oncology* **2011**, *6*, 1260. (c) Faivre *et. al.*, *Annals of Oncology* **2017**, *28*, 339. (d) Elgebaly

et. al., Breast Disease **2016**, 36, 91.

³(a) Kim *et al.*, *Investigative Ophthalmology & Visual Science* **2021**, 62, 447. (b) Kim *et al.*, *American Academy of Ophthalmology 2020 Annual Meeting*, Las Vegas, NV, **2020**, PO441.

⁴ <https://clinicaltrials.gov>. Accessed on January 19th, 2022. [Advanced search details] Status (Recruitment): "Active, not recruiting"; Intervention/treatment: "sunitinib"; irrelevant search results excluded.

⁵Sangwan *et al.*, *International Research Journal of Pure & Applied Chemistry* **2015**, 5, 352. Note: It is also notable that novel salt forms of sunitinib with adipate and nicotinate show higher solubility in water than that of malate salt form.

⁶(a) Joseph *et al.*, *International Journal of Biological Macromolecules* **2016**, 82, 952. (b) Bhatt *et al.*, *AAPS PharmSciTech* **2019**, 20, 281.

⁷Navid *et al.*, *The Annals of Pharmacotherapy* **2008**, 42, 962.

⁸Streets *et al.*, *Scientia Pharmaceutica* **2020**, 88, 30.

⁹(a) Kassem *et al.*, Chapter 9. In *Profiles of Drug Substances, Excipients and Related Methodology* Volume 37, Brittain Eds., Elsevier, **2012**, 363. (b) Manley *et al.*, *Journal of Organic Chemistry* **2003**, 68, 6447. (c) Wang *et al.*, *Bioorganic & Medicinal Chemistry Letter* **2005**, 15, 4380.

¹⁰Following article reports comprehensive physicochemical characteristics of sunitinib malate, however the assigned ¹H, ¹³C, and ¹⁵N NMR spectra acquired in DMSO-d₆ are not provided: Sidoryk *et al.*, *Journal of Pharmaceutical Sciences* **2013**, 102, 706.

¹¹(a) Saurí *et al.*, *Concepts in Magnetic Resonance Part A* **2016**, 44A, 227. (b) Nyberg *et al.*, *Journal of the American Chemical Society* **2005**, 127, 6154.